For decades, the global effort to treat Alzheimer’s disease has centered on a single target: amyloid beta. Billions of dollars have been poured into clinical trials designed to clear these protein deposits from the brain. Now, a biochemist at the University of California, Santa Cruz, argues that this narrow focus may have blinded the scientific community to another significant contributor to the disease.
Jevgenij Raskatov, a professor in the chemistry and biochemistry department, published a commentary in the journal ChemBioChem highlighting research on a smaller, closely related peptide known as P3. While amyloid beta has dominated the field, P3 was long considered an innocent bystander. Raskatov contends that this assumption is incorrect and that P3 may play a direct role in the nerve cell damage characteristic of the condition.
Challenging the Amyloid Beta Dominance
Alzheimer’s disease affects approximately 35 million people worldwide and generates annual costs exceeding $800 billion. The number of patients is projected to double by 2050. Despite extensive research, developing effective treatments has proven difficult. More than 400 clinical trials have investigated potential drugs, with most targeting amyloid beta. Many of these efforts have failed, and some approved antibody treatments have been associated with serious complications, including brain hemorrhages.
Amyloid beta originates from a larger protein embedded in cell membranes called the Amyloid Precursor Protein (APP). When enzymes cut this protein, they release amyloid beta peptides of varying lengths. Researchers have focused heavily on two versions, A40 and A42, because they are prone to sticking together and forming toxic aggregates. Raskatov argues that the benefits achieved so far remain limited, underscoring the need to investigate other biological processes.
“Progress has been extremely slow, and the current state of the art in Alzheimer’s therapy leaves much to be desired,” Raskatov said. “We need fundamentally new approaches to the problem.”
P3 Peptide Formation and Toxicity
P3 forms through a different processing pathway of the APP protein. In this sequence, an enzyme called beta-secretase acts first, followed by gamma-secretase. For years, scientists assumed that P3 was incapable of forming amyloid deposits and would simply dissolve in water. These assumptions were never adequately verified, yet they helped establish the view that the peptide was unlikely to matter in Alzheimer’s disease.
Raskatov and his laboratory spent five years testing these long-standing beliefs. Their studies demonstrated that P3 can form amyloid deposits at least as readily as amyloid beta. In fact, their experiments showed that P3 produces these aggregates more rapidly. The researchers also found evidence that P3 itself may be harmful to neurons, although its toxicity appears lower than that of amyloid beta.
Raskatov has proposed renaming the peptide “Amyloid P” or AP to better distinguish it from amyloid beta and reflect its ability to form aggregates. He noted that an independent research group in the United Kingdom has confirmed and expanded upon his team’s findings. Other laboratories are now beginning to investigate how P3 and amyloid beta interact, including whether their relationship affects the accumulation and toxicity of these peptides.
Scientific Misinterpretation and Future Directions
The emerging evidence challenges the long-held assumption that P3 is biologically harmless. However, Raskatov has encountered a troubling problem regarding how other scientists have interpreted his team’s discoveries. He identified at least four papers published in respected, peer-reviewed journals that cited his laboratory’s research as evidence that P3 was harmless and unable to form amyloid deposits. His team’s experiments had demonstrated precisely the opposite.
“This is exactly the opposite of what we have actually shown,” Raskatov said. “We remain in the dark on how this sort of grand confusion may have come about. Clearly, there is more work ahead of us.”
David Teplow, an emeritus professor of neurology at UCLA, provided an independent evaluation of Raskatov’s research. Teplow concluded that scientists are beginning to reconsider the narrow focus on amyloid beta. He stated that this reevaluation has far-reaching consequences for both basic science and clinical research into the causes and treatment of Alzheimer’s disease.
Understanding Alzheimer’s may require looking beyond amyloid beta alone. By examining P3 and its interactions with other amyloid peptides, researchers hope to gain a more complete picture of the processes that damage brain cells. This broader perspective could potentially identify new directions for treatment and improve outcomes for patients living with the disease.
Source: ScienceDaily
